Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes

International Journal of Clinical Practice

Volumn 67, Issue 9, 2013, Pages 876-887

  Mudaliar, S ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; TROGLITAZONE; VILDAGLIPTIN;

ANTIDIABETIC ACTIVITY; BLADDER CANCER; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETOGENESIS; DIET THERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EARLY INTERVENTION; FOOT EDEMA; FRACTURE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEREDITY; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER TOXICITY; MOLECULAR PATHOLOGY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT EDUCATION; PHYSICAL ACTIVITY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

DECISION MAKING; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; RISK REDUCTION BEHAVIOR;

EID: 84882416143     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12154     Document Type: Review

References (64)

1. DeFronzo RA, Banerji MA, Bray GA, et al. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010; 53: 435-45.
2. Freeman JS,. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc 2010; 85: S5-14.
3. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35: S11-63.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (Suppl. 1): 1364-79.
5. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-59.
6. Holman RR,. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40 (Suppl.): S21-5.
7. Festa A, Williams K, Hanley AJ, Haffner SM,. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 2008; 57: 1638-44.
8. DeFronzo RA,. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.
9. Ferrannini E, Gastaldelli A, Miyazaki Y, et al. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
10. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
11. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
12. Chon S, Oh S, Kim SW, et al. The effect of early insulin therapy on pancreatic beta-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med 2010; 25: 273-81.
13. Leahy JL, Hirsch IB, Peterson KA, Schneider D,. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 4206-16.
14. Saisho Y, Tanaka K, Abe T, et al. Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis. Endocr J 2012; 59: 187-95.
15. DeFronzo RA, Tobin JD, Andres R,. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
16. Byrne MM, Sturis J, Polonsky KS,. Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol 1995; 268: E21-7.
17. Wallace TM, Levy JC, Matthews DR,. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
18. Mykkanen L, Zaccaro DJ, Hales CN, et al. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia 1999; 42: 1060-6.
19. Toffolo G, Breda E, Cavaghan MK, et al. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab 2001; 280: E2-10.
20. Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-6.
21. Turner RC, Cull CA, Frighi V, Holman RR,. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12.
22. UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-58.
23. Colagiuri S, Cull CA, Holman RR, UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 2002; 25: 1410-7.
24. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
25. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes 2011; 60: 1552-60.
26. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.
28. Del Prato S,. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009; 52: 1219-26.
29. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
30. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
31. Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379: 2243-51.
32. de Mello VD, Lindstrom J, Eriksson J, et al. Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: the Finnish Diabetes Prevention Study. Diabetes Care 2012; 35: 211-7.
33. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-803.
34. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-22.
35. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
36. Hanley AJ, Zinman B, Sheridan P, et al. Effect of rosiglitazone and ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care 2010; 33: 608-13.
37. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-15.
38. U. S. Food Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. 2010. http://www.fda.gov/newsevents/newsroom/ pressannouncements/UCM226975.htm. (accessed 4 March 2013).
39. ACTOS (pioglitazone hydrochloride). Full Prescribing Information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2011.
40. Drucker DJ,. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-40.
41. McGill JB,. Insights from the Liraglutide Clinical Development Program-the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009; 121: 16-25.
42. Charbonnel B, Cariou B,. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab 2011; 13: 99-117.
43. Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 348-56.
44. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-78.
45. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-30.
46. DeFronzo RA, Triplitt C, Qu Y, et al. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010; 33: 951-7.
47. Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2041-7.
48. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-8.
49. Defronzo RA, Abdul-Ghani MA,. Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 2011; 96: 2354-66.
50. Armato J, Defronzo RA, Abdul-Ghani M, Ruby R,. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta cell dysfunction. Endocr Pract 2012; 18: 342-50.
51. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258-67.
52. Cernea S, Raz I,. Therapy in the early stage: incretins. Diabetes Care 2011; 34 (Suppl. 2): S264-71.
53. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q,. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315-7.
54. Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009; 57: 2011-9.
55. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-87.
56. Williams-Herman D, Xu L, Teng R, et al. Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 67-76.
57. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 2401-11.
58. Ristic S, Byiers S, Foley J, Holmes D,. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-8.
59. Nyalakonda K, Sharma T, Ismail-Beigi F,. Preservation of beta-cell function in type 2 diabetes. Endocr Pract 2010; 16: 1038-55.
60. Alvarsson M, Berntorp K, Fernqvist-Forbes E, et al. Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. Rev Diabet Stud 2010; 7: 225-32.
61. Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009; 32: 1789-95.
62. Xu W, Li YB, Deng WP, et al. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chin Med J (Engl) 2009; 122: 2554-9.
63. Korytkowski M,. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26: S18-24.
64. Brunton SA, Davis SN, Renda SM,. Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentation. Clin Cornerstone 2006; 8 (Suppl. 2): S6-18.